Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature

Azacitidine is the first drug to demonstrate a survival benefit for patients with MDS. However, only half of patients respond and almost all patients eventually relapse. Limited and conflicting data are available on predictive factors influencing response. We analyzed 128 patients from two instituti...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Kuendgen, Andrea, Müller-Thomas, Catharina, Lauseker, Michael, Haferlach, Torsten, Urbaniak, Petra, Schroeder, Thomas, Brings, Carolin, Wulfert, Michael, Meggendorfer, Manja, Hildebrandt, Barbara, Betz, Beate, Royer-Pokora, Brigitte, Gattermann, Norbert, Haas, Rainer, Germing, Ulrich, Götze, Katharina S.
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2018
Fag:
Clinical Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021252/
https://ncbi.nlm.nih.gov/pubmed/29963245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25328
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker